Kindly Md, Inc. shares rise 1.71% premarket after Arecor Therapeutics announced a co-development agreement with a US insulin pump device company.

Kindly Md, Inc. rose 1.71% in premarket trading, with the company announcing a co-development agreement with a US insulin pump device company for AT278, an ultra-concentrated and ultra-rapid acting insulin designed for next-generation automated insulin delivery systems. The agreement includes a commitment of up to $1.3 million each from Arecor and Sequel Med Tech, LLC to fund development work for a pivotal Phase 2 trial.